Regeneron - PDFSEARCH.IO - Document Search Engine

Regeneron
Results: 62

#	Item
31	PRESS RELEASE Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps Paris and Tarrytown, N.Y. – September 30, [removed]Sanofi and Regeneron Pharma Add to Reading List Source URL: en.sanofi.com Language: English - Date: 2014-10-10 07:50:13 Immunology Rhinology Regeneron Immune system Sinusitis Atopic dermatitis Nasal polyp Asthma Allergy Medicine Health Type 1 hypersensitivity
32	COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent de premiers résultats positifs sur le dupilumab dans le traitement de la polypose naso-sinusienne Paris (France) et Tarrytown (New York) - Le 30 septembre[removed]Sano Add to Reading List Source URL: www.sanofi.com Language: French - Date: 2014-10-10 00:22:07
33	November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I Add to Reading List Source URL: files.shareholder.com Language: English Medicine Immunosuppressants Macrolides Atopic dermatitis Regeneron Eczema Pharmacology Dermatitis Atopy Health Type 1 hypersensitivity Immune system
34	April 3, 2014 Regeneron Announces Initiative for STEM Education in Hudson Valley Fellowship Program in Collaboration with NASA, Teachers College, Columbia University and STEM Education Leadership Center TARRYTOWN, N.Y., Add to Reading List Source URL: files.shareholder.com Language: English George Yancopoulos Regeneron
35	COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent la présentation des résultats positifs détaillés de quatre études pivots sur l’alirocumab au Congrès 2014 de l’ESC - L’alirocumab, un produit expérimental Add to Reading List Source URL: www.sanofi.com Language: French - Date: 2014-10-10 05:15:08
36	COMMUNIQUÉ DE PRESSE Sanofi et Regeneron vont présenter les résultats de quatre essais cliniques de Phase 3 consacrés à l’alirocumab à la séance Hot Line du Congrès 2014 de l’ESC Paris (France) et Tarrytown Add to Reading List Source URL: www.sanofi.com Language: French - Date: 2014-10-10 00:18:53
37	PRESS RELEASE Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 Paris, France, and Tarrytown, NY, August 25, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) Add to Reading List Source URL: en.sanofi.com Language: English - Date: 2014-10-09 14:57:16 Organofluorides Medicine Pharmaceutical industry Monoclonal antibodies Sanofi Forward-looking statement Ezetimibe Pharmaceutical sciences Regeneron Chemistry
38	Sanofi and Regeneron Present Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress[removed]Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C Add to Reading List Source URL: en.sanofi.com Language: English - Date: 2014-10-10 12:14:27 Clinical research Pharmacology Organofluorides Phenols Ezetimibe Lactams Statin Low-density lipoprotein Familial hypercholesterolemia Medicine Chemistry Health
39	Nueva Droga, Zaltrap, Aprobada por la FDA para Pacientes con Cáncer Metastásico Estadio IV  ¿Qué es Zaltrap? o Zaltrap fue desarrollado por Sanofi en asociación con Regeneron Pharmaceuticals. o Zaltrap es el prim Add to Reading List Source URL: www.ccalliance.org Language: Spanish - Date: 2012-08-14 23:27:37
40	July 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis Results from Earlier Clinical Trials Published Today in the New England Add to Reading List Source URL: files.shareholder.com Language: English Immune system Atopic dermatitis Regeneron Atopy Eczema Dermatitis Asthma Allergy Placebo Medicine Health Type 1 hypersensitivity

UPDATE